Jul. 22 at 1:19 PM
$KPRX Today we were issued a patent (USPTO # 12,364,680), which extends protection for KIO-104 in treating ocular inflammation, uveitis, AMD, and post-surgical complications. More specifically, the patent strengthens IP around dosing, formulation, and methods, extending exclusivity to 2043.
KIO-104 is a potent small molecule in development for inflammatory retinal diseases with the goal of providing an alternative to steroids or systemic anti-inflammatory drugs. A multicenter Phase 2 clinical trial, the KLARITY study, is currently screening patients to investigate KIO-104 at two dose levels across several forms of inflammatory retinal disease.
Read more > https://ir.kiorapharma.com/news-events/news-releases/detail/235/kiora-pharmaceuticals-granted-u-s-patent-expanding-protection-for-kio-104-in-the-treatment-of-ocular-disease
